Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability,
PK and efficacy of ZN-A-1041 as a monotherapy or in combination with Capecitabine in patients
with HER2-positive advanced solid tumors with or without brain metastases.
The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041
monotherapy), phase 1b (dose escalation with ZN-A-1041 and Capecitabine combination therapy)
and phase 1c (dose expansion with ZN-A-1041 and Capecitabine combination therapy).